Developer docs
API playgroundTry for free, no card

Search company profiles

Alfred Research Alliance

Full company profile

uuid002gwl5

Namestring
Alfred Research Alliance
Legal namestring
Alfred Research Alliance
Company typeenum
Private
Founded yearint
1995
Descriptiontext

Alfred Research Alliance (ARA) is a not-for-profit research consortium established in 1995 (as AMREP, renamed in 2016) that brings together eight member organizations co-located on the Alfred Hospital precinct in Melbourne, Australia. Its members conduct biomedical, clinical, and public health research spanning infectious disease, cardiovascular and metabolic disease, neuroscience, cancer, and population health. The alliance functions as a coordination and shared-infrastructure platform rather than a direct employer of researchers, with the central entity reporting 11-50 staff while supporting approximately 1,328 students on campus and a broader research workforce distributed across member institutes.

ARA's core capabilities rest on shared translational infrastructure: 31 clinical trial units hosting 748+ active trials with ~7,000 patients enrolled, multiple long-running biobanks (including ASPREE and AusDiab), a Total-Body Quadra PET scanner installed in 2025 (A$24M), GMP-certified bioanalytical services (historically via 360biolabs, now divested to BioAgilytix), and early-phase clinical trial capacity through member Nucleus Network, which expanded to the UK via the 2025 acquisition of Hammersmith Medicines Research. Alliance researchers produce on the order of 2,800 peer-reviewed publications per year and apply AI/ML in cardiology (Prof Tom Marwick) and epilepsy (Prof Patrick Kwan), among other areas.

The alliance's revenue mechanics are predominantly grant-based rather than commercial: A$332M in external research funding flowed through members in 2025, including A$42.9M in NHMRC Investigator Grants, supplemented by commercial clinical trial services (Nucleus Network as a global early-phase CRO), philanthropy (Gates Foundation malaria work), and partnership-based funding (e.g., the 2026 VARAP Aboriginal Health Accord). Customer relationships span federal research funders, international philanthropy, pharma sponsors, patients, and students, with no single counterparty dominating. Governance is in the process of transitioning to Bayside Health, the entity formed by the merger of Alfred Health and ARA effective January 2026.

Short descriptiontext

Alfred Research Alliance is a not-for-profit consortium of eight Melbourne-based research organizations conducting biomedical, clinical, and public health research. It coordinates 31 clinical trial units running 748+ trials, supports ~7,000 patients and 1,328 students, and channels A$332M in annual external research funding.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomedical research, clinical trials, translational medicine, public health research, preclinical imaging
Industry3 codes
PRIMARYEDAHAGAI
Biomedical Sciences & Medical Research Institutes (University-Based)
Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Membership Organizations8600
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Biomedical Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Research Grants and Funding
TypeSubscription Recurring
Description

The alliance generates revenue through competitive research grants from government bodies including NHMRC, Medical Research Future Fund, and other national/international funding bodies. Alliance members secured $332M in total external funding in 2025.

alfredresearchalliance.org.au
2Clinical Trial Services
TypeProfessional Services
Description

Revenue generated through contract research services via member organizations like 360biolabs and Nucleus Network for pharmaceutical and biotech companies conducting clinical trials.

alfredresearchalliance.org.au
3Education and Training
TypeSubscription Recurring
Description

Revenue from postgraduate education, nursing and allied health programs, and short courses offered by member universities.

alfredresearchalliance.org.au
4Platform Services and Facilities Access
TypeUsage Based
Description

Fee-for-service access to specialized research platforms including imaging, cytometry, bioinformatics, and histology facilities for external researchers and industry.

alfredresearchalliance.org.au
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Alfred Research Alliance is a consortium of eight healthcare, university, and medical research organizations operating a co-located biomedical research precinct in Melbourne. It delivers translational research, clinical trials (including first-in-human studies), specialized research platform services (flow cytometry, preclinical imaging, biobanks, bioinformatics), and postgraduate education programs. Activities span basic science, clinical trials, and public health implementation, supported by $332M in annual external research funding.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 748 clinical trials open across 31 clinical trial units including 120 first-in-human studies
+3 more records
Product overview1 text field

Alfred Research Alliance is a collaborative research partnership among eight leading healthcare, education, and medical research organizations (Alfred Health, Monash University, Baker Heart and Diabetes Institute, Burnet Institute, Deakin University, La Trobe University, Nucleus Network, and 360biolabs) operating across a single research precinct in Melbourne. Rather than a unified software product, the Alliance provides a portfolio of shared research infrastructure, capabilities, and services including: specialized research platforms (ARAFlowCore for flow cytometry, ARA-MBI Preclinical Imaging Facility with MRI/PET/CT/MPI, Translational Cardiology Centre, Optima decision science tools); biobanks and clinical registries (ASPREE, AusDiab, Victorian HIV Bank, Alfred Cancer Biobank, Alfred Neuroscience Bio-databank); clinical trials services (748 trials across 31 units); education programs (postgraduate, nursing, allied health); and the Innovation & Education Hub (HUB spaces). These integrated capabilities enable translational research from basic science through to clinical application, positioning the precinct as one of Australia's largest biomedical research centers.

Product and service11 records
1Clinical Trials Services
CategoryClinical trial services
Description

End-to-end clinical trials services spanning all phases from Phase I first-in-human studies through to late-stage and public health implementation, accessible across 31 clinical trial units. Supports pharmaceutical, biotech, and academic sponsors with experienced clinicians and patient access.

2Education Programs
CategoryEducation and training
Description

Comprehensive education offerings including postgraduate study, nursing and allied health programs, short courses, and scholarships/honours programs delivered through member universities. Bridges academic theory and real-world healthcare with 1,328 students welcomed to campus in 2025.

3Clinical Registries and Biobanks
CategoryBiobank and registry services
Description

Collection of specialized biobanks including ASPREE Healthy Ageing Biobank, AusDiab study, Victorian HIV Blood and Tissue Storage Bank, Alfred Brain Tumour Bio-databank, Alfred Cancer Biobank, and Alfred Neuroscience Bio-databank supporting population health and clinical research.

4ARAFlowCore (Flow Cytometry Services)
CategoryResearch platform technology
Description

World-class flow cytometry services providing cell sorting and analysis in PC2-compliant laboratories, with spectral technology capable of visualizing 40+ fluorescent parameters on a single cell.

5ARA-MBI Preclinical Imaging Facility
CategoryPreclinical imaging services
Description

State-of-the-art preclinical imaging facility including 9.4T MRI, NanoPET-CT imaging system, and world-first magnetic particle imaging (MPI) system paired with localized hyperthermia for small animal research imaging.

6Translational Cardiology Centre
CategorySpecialized cardiac research platform
Description

Highly specialized cardiac research platform with expertise in myocardial infarction, cardiac arrest, and heart failure models, featuring state-of-the-art surgical and imaging technologies for preclinical trial design and delivery.

7Optima Decision Science Tools
CategoryPublic health decision science software
Description

Mathematical modeling suite for public health decision-making developed in partnership with the World Bank. Open-access web-based tools for resource allocation optimization in HIV, hepatitis C, COVID-19, nutrition, tuberculosis, malaria, and maternal/child health.

8Bioinformatics Program
CategoryBioinformatics services
Description

Baker Heart and Diabetes Institute's bioinformatics capability providing data analysis across genomics, epigenomics, transcriptomics, proteomics, metabolomics, and metagenomics using statistical analysis, machine learning, and network analysis.

9HUB Innovation & Education Spaces
CategoryInnovation and education facilities
Description

Innovation and education hub featuring Town Square for collaboration, Learning Zone with technology-enabled flexible learning areas, The Terraces seminar space, and Ian Potter Reading Room quiet library space.

10ACRF Centre for Dynamic Immuno-Oncology
CategoryCancer research and treatment
Description

Australian Cancer Research Foundation-funded center at the Paula Fox Melanoma and Cancer Centre advancing immunotherapy as a leading form of cancer treatment through understanding patient unique immune responses in real-time.

11Baker Heart & Diabetes Institute Research
CategoryCardiovascular and metabolic disease research
Description

Research focused on heart disease, diabetes, and related conditions using ground-breaking bioengineering techniques, novel disease prediction and detection methods, and big data and AI approaches for better prevention, diagnosis, and treatment.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BioAgilytix Labs, headquartered in North Carolina with labs in Boston and Hamburg, acquired 360biolabs in 2021. 360biolabs was majority owned by Burnet Institute and received several hundred million dollars in revenue from the sale. The acquisition adds to BioAgilytix's international presence and quality systems (ISO/IEC 17025, ISO 15189, GLP and GCLP) in Melbourne.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Nucleus Network acquired Hammersmith Medicines Research, extending their footprint from Australia and US into the UK, strengthening early-phase clinical trial capabilities globally.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

International research collaboration with Prof James Beeson and Burnet's Malaria Immunity and Vaccines Group to conduct clinical studies in East Africa identifying antibodies for malaria vaccine development.

4Infectious Diseases Research Collaboration (Uganda)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

International collaboration led by Isaac Sewanyana for malaria vaccine research studies in Uganda, part of Gates Foundation funded projects.

alfredresearchalliance.org.au
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Prof Faith Osier from Imperial College London on malaria vaccine development research in East Africa.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Pras Jagannathan from Stanford University on malaria vaccine development research.

7PATH
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with PATH, a US-based not-for-profit organization, on global health vaccine development initiatives.

alfredresearchalliance.org.au
Strategic tierCoreTypeStrategic or Co-development Partner
Description

In early 2026, Alfred Research Alliance became a signatory to the Victorian Aboriginal Health, Medical and Wellbeing Research Accord Project (VARAP), an innovative framework designed to guide and govern health research impacting Aboriginal and Torres Strait Islander people in Victoria.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with University of Melbourne in the Pathway to Clean Indoor Air project consortium, with Prof Jason Monty leading the engineering domain.

10THRIVE (Training Centre for Advanced Building Systems Against Airborne Infection Transmission)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with THRIVE in the Pathway to Clean Indoor Air project to evaluate indoor air quality and develop solutions for airborne infection transmission.

alfredresearchalliance.org.au
Strategic tierMinorTypeStrategic or Co-development Partner
Description

AWS collaborated with the consortium to establish practical steps for an integrated indoor air quality solution, bringing real-time air quality monitoring network experience.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Burnet Institute is majority owner of 360biolabs and receives revenue from the sale to BioAgilytix. Burnet Institute is a foundation partner of the Australian Institute for Infectious Disease (AIID).

13Australasian Leukaemia and Lymphoma Group
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ALLG is a not-for-profit blood cancer clinical trial research group that partnered with Prof David Curtis on blood stem cell transplant research that changed 40 years of standard practice.

alfredresearchalliance.org.au
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
1Brisbane Diamantina Health Partners
TypeDirect peer
Description

NHMRC-accredited AHSC covering Brisbane's major hospitals and universities (UQ, QUT). Competes with ARA for translational research scale and industry-sponsored trials in Australia.

2Parkville Precinct Partnership (WEHI, Peter Mac, Doherty Institute, Melbourne Neuroscience Centre)
TypeDirect peer
Description

Major Melbourne biomedical research cluster around Walter and Eliza Hall Institute, Peter MacCallum Cancer Centre, and the Doherty Institute. Comparable in scale to ARA, focused on cancer, immunology, and infectious disease, offering an alternative precinct for researchers and industry CRO partnerships.

TypeEmerging player
Description

London-based biomedical discovery research institute with strong translational focus and major funder partnerships (Wellcome, CRUK, MRC). Comparable in biomedical research density and public-private funding model, though structured as a single institute rather than a consortium.

TypeDirect peer
Description

UK-based academic health science centre combining King's College London, Guy's and St Thomas', King's College Hospital, and South London and Maudsley. Closest international analog to ARA's AMC-affiliated consortium structure with translational research focus.

TypeDirect peer
Description

NHMRC-accredited AHSC spanning Monash Health, Monash University, Hudson Institute, and other partners. Overlaps significantly with ARA given Monash University's dual membership; competes for translational research funding and clinical trial activity in Melbourne.

TypeRegional player
Description

Major state-based biomedical research institute in Adelaide that similarly aggregates research infrastructure, clinical trial activity, and university partnerships. Operates in a different metro market but is structurally analogous as a multi-stakeholder research enterprise.

TypeDirect peer
Description

MACH is a Victorian NHMRC-accredited Advanced Health Research and Translation Centre linking several Melbourne hospitals and universities — the same AMC-affiliated consortium model as ARA. Directly comparable as a competing Melbourne-based academic health science partnership focused on translational research.

TypeDirect peer
Description

NHMRC-accredited AHSC bringing together several Sydney-based hospitals, universities, and research institutes. Closest geographic peer for translational research funding and clinical trial competition in Australia's largest metro market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alfred Research Alliance

Biomedical Research Servicesalfredresearchalliance.org.au

Alfred Research Alliance is a not-for-profit consortium of eight Melbourne-based research organizations conducting biomedical, clinical, and public health research. It coordinates 31 clinical trial units running 748+ trials, supports ~7,000 patients and 1,328 students, and channels A$332M in annual external research funding.

What Alfred Research Alliance does

Alfred Research Alliance (ARA) is a not-for-profit research consortium established in 1995 (as AMREP, renamed in 2016) that brings together eight member organizations co-located on the Alfred Hospital precinct in Melbourne, Australia. Its members conduct biomedical, clinical, and public health research spanning infectious disease, cardiovascular and metabolic disease, neuroscience, cancer, and population health. The alliance functions as a coordination and shared-infrastructure platform rather than a direct employer of researchers, with the central entity reporting 11-50 staff while supporting approximately 1,328 students on campus and a broader research workforce distributed across member institutes.

ARA's core capabilities rest on shared translational infrastructure: 31 clinical trial units hosting 748+ active trials with ~7,000 patients enrolled, multiple long-running biobanks (including ASPREE and AusDiab), a Total-Body Quadra PET scanner installed in 2025 (A$24M), GMP-certified bioanalytical services (historically via 360biolabs, now divested to BioAgilytix), and early-phase clinical trial capacity through member Nucleus Network, which expanded to the UK via the 2025 acquisition of Hammersmith Medicines Research. Alliance researchers produce on the order of 2,800 peer-reviewed publications per year and apply AI/ML in cardiology (Prof Tom Marwick) and epilepsy (Prof Patrick Kwan), among other areas.

The alliance's revenue mechanics are predominantly grant-based rather than commercial: A$332M in external research funding flowed through members in 2025, including A$42.9M in NHMRC Investigator Grants, supplemented by commercial clinical trial services (Nucleus Network as a global early-phase CRO), philanthropy (Gates Foundation malaria work), and partnership-based funding (e.g., the 2026 VARAP Aboriginal Health Accord). Customer relationships span federal research funders, international philanthropy, pharma sponsors, patients, and students, with no single counterparty dominating. Governance is in the process of transitioning to Bayside Health, the entity formed by the merger of Alfred Health and ARA effective January 2026.

Alfred Research Alliance firmographics

Firmographics
Name
Alfred Research Alliance
Legal name
Alfred Research Alliance
Website
https://alfredresearchalliance.org.au
Company type
Private
Founded year
1995
Operating status
Operating
Headcount range
1–10 employees
Short description
Alfred Research Alliance is a not-for-profit consortium of eight Melbourne-based research organizations conducting biomedical, clinical, and public health research. It coordinates 31 clinical trial units running 748+ trials, supports ~7,000 patients and 1,328 students, and channels A$332M in annual external research funding.
Ownership category
akta.pro rank

Alfred Research Alliance industry classification

Industry
Product category
Biomedical Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Membership Organizations (8600), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYEDAHAGAI
Biomedical Sciences & Medical Research Institutes (University-Based)
Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)

Keywords

  • Biomedical research
  • Clinical trials
  • Translational medicine
  • Public health research
  • Preclinical imaging

Where Alfred Research Alliance is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Alfred Research Alliance business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

  1. Research Grants and Funding: The alliance generates revenue through competitive research grants from government bodies including NHMRC, Medical Research Future Fund, and other national/international funding bodies. Alliance members secured $332M in total external funding in 2025.
  2. Clinical Trial Services: Revenue generated through contract research services via member organizations like 360biolabs and Nucleus Network for pharmaceutical and biotech companies conducting clinical trials.
  3. Education and Training: Revenue from postgraduate education, nursing and allied health programs, and short courses offered by member universities.
  4. Platform Services and Facilities Access: Fee-for-service access to specialized research platforms including imaging, cytometry, bioinformatics, and histology facilities for external researchers and industry.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Alfred Research Alliance product offering

Product offering

Core offering

Alfred Research Alliance is a consortium of eight healthcare, university, and medical research organizations operating a co-located biomedical research precinct in Melbourne. It delivers translational research, clinical trials (including first-in-human studies), specialized research platform services (flow cytometry, preclinical imaging, biobanks, bioinformatics), and postgraduate education programs. Activities span basic science, clinical trials, and public health implementation, supported by $332M in annual external research funding.

Product overview

Alfred Research Alliance is a collaborative research partnership among eight leading healthcare, education, and medical research organizations (Alfred Health, Monash University, Baker Heart and Diabetes Institute, Burnet Institute, Deakin University, La Trobe University, Nucleus Network, and 360biolabs) operating across a single research precinct in Melbourne. Rather than a unified software product, the Alliance provides a portfolio of shared research infrastructure, capabilities, and services including: specialized research platforms (ARAFlowCore for flow cytometry, ARA-MBI Preclinical Imaging Facility with MRI/PET/CT/MPI, Translational Cardiology Centre, Optima decision science tools); biobanks and clinical registries (ASPREE, AusDiab, Victorian HIV Bank, Alfred Cancer Biobank, Alfred Neuroscience Bio-databank); clinical trials services (748 trials across 31 units); education programs (postgraduate, nursing, allied health); and the Innovation & Education Hub (HUB spaces). These integrated capabilities enable translational research from basic science through to clinical application, positioning the precinct as one of Australia's largest biomedical research centers.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Trials Services End-to-end clinical trials services spanning all phases from Phase I first-in-human studies through to late-stage and public health implementation, accessible across 31 clinical trial units. Supports pharmaceutical, biotech, and academic sponsors with experienced clinicians and patient access.
  • Education Programs Comprehensive education offerings including postgraduate study, nursing and allied health programs, short courses, and scholarships/honours programs delivered through member universities. Bridges academic theory and real-world healthcare with 1,328 students welcomed to campus in 2025.
  • Clinical Registries and Biobanks Collection of specialized biobanks including ASPREE Healthy Ageing Biobank, AusDiab study, Victorian HIV Blood and Tissue Storage Bank, Alfred Brain Tumour Bio-databank, Alfred Cancer Biobank, and Alfred Neuroscience Bio-databank supporting population health and clinical research.
  • ARAFlowCore (Flow Cytometry Services) World-class flow cytometry services providing cell sorting and analysis in PC2-compliant laboratories, with spectral technology capable of visualizing 40+ fluorescent parameters on a single cell.
  • ARA-MBI Preclinical Imaging Facility State-of-the-art preclinical imaging facility including 9.4T MRI, NanoPET-CT imaging system, and world-first magnetic particle imaging (MPI) system paired with localized hyperthermia for small animal research imaging.
  • Translational Cardiology Centre Highly specialized cardiac research platform with expertise in myocardial infarction, cardiac arrest, and heart failure models, featuring state-of-the-art surgical and imaging technologies for preclinical trial design and delivery.
  • Optima Decision Science Tools Mathematical modeling suite for public health decision-making developed in partnership with the World Bank. Open-access web-based tools for resource allocation optimization in HIV, hepatitis C, COVID-19, nutrition, tuberculosis, malaria, and maternal/child health.
  • Bioinformatics Program Baker Heart and Diabetes Institute's bioinformatics capability providing data analysis across genomics, epigenomics, transcriptomics, proteomics, metabolomics, and metagenomics using statistical analysis, machine learning, and network analysis.
  • HUB Innovation & Education Spaces Innovation and education hub featuring Town Square for collaboration, Learning Zone with technology-enabled flexible learning areas, The Terraces seminar space, and Ian Potter Reading Room quiet library space.
  • ACRF Centre for Dynamic Immuno-Oncology Australian Cancer Research Foundation-funded center at the Paula Fox Melanoma and Cancer Centre advancing immunotherapy as a leading form of cancer treatment through understanding patient unique immune responses in real-time.
  • Baker Heart & Diabetes Institute Research Research focused on heart disease, diabetes, and related conditions using ground-breaking bioengineering techniques, novel disease prediction and detection methods, and big data and AI approaches for better prevention, diagnosis, and treatment.

Quantifiable outcome

  • 748 clinical trials open across 31 clinical trial units including 120 first-in-human studies
  • +3 more outcomes

Companies that use Alfred Research Alliance

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Alfred Research Alliance technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature9 records

Alfred Research Alliance partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • BioAgilytix LabscoreStrategic or Co-development PartnerBioAgilytix Labs, headquartered in North Carolina with labs in Boston and Hamburg, acquired 360biolabs in 2021. 360biolabs was majority owned by Burnet Institute and received several hundred million dollars in revenue from the sale. The acquisition adds to BioAgilytix's international presence and quality systems (ISO/IEC 17025, ISO 15189, GLP and GCLP) in Melbourne.
  • Hammersmith Medicines ResearchminorStrategic or Co-development PartnerNucleus Network acquired Hammersmith Medicines Research, extending their footprint from Australia and US into the UK, strengthening early-phase clinical trial capabilities globally.
  • Kenya Medical Research InstitutecoreStrategic or Co-development PartnerInternational research collaboration with Prof James Beeson and Burnet's Malaria Immunity and Vaccines Group to conduct clinical studies in East Africa identifying antibodies for malaria vaccine development.
  • Infectious Diseases Research Collaboration (Uganda)coreStrategic or Co-development PartnerInternational collaboration led by Isaac Sewanyana for malaria vaccine research studies in Uganda, part of Gates Foundation funded projects.
  • Imperial College LondoncoreStrategic or Co-development PartnerCollaboration with Prof Faith Osier from Imperial College London on malaria vaccine development research in East Africa.
  • Stanford UniversitycoreStrategic or Co-development PartnerCollaboration with Pras Jagannathan from Stanford University on malaria vaccine development research.
  • PATHcoreStrategic or Co-development PartnerPartnership with PATH, a US-based not-for-profit organization, on global health vaccine development initiatives.
  • marra ngarrgoo, marra goorri (VARAP)coreStrategic or Co-development PartnerIn early 2026, Alfred Research Alliance became a signatory to the Victorian Aboriginal Health, Medical and Wellbeing Research Accord Project (VARAP), an innovative framework designed to guide and govern health research impacting Aboriginal and Torres Strait Islander people in Victoria.
  • University of MelbournecoreStrategic or Co-development PartnerPartnership with University of Melbourne in the Pathway to Clean Indoor Air project consortium, with Prof Jason Monty leading the engineering domain.
  • THRIVE (Training Centre for Advanced Building Systems Against Airborne Infection Transmission)coreStrategic or Co-development PartnerPartnership with THRIVE in the Pathway to Clean Indoor Air project to evaluate indoor air quality and develop solutions for airborne infection transmission.
  • Amazon Web Services (AWS)minorStrategic or Co-development PartnerAWS collaborated with the consortium to establish practical steps for an integrated indoor air quality solution, bringing real-time air quality monitoring network experience.
  • Burnet InstitutecoreStrategic or Co-development PartnerBurnet Institute is majority owner of 360biolabs and receives revenue from the sale to BioAgilytix. Burnet Institute is a foundation partner of the Australian Institute for Infectious Disease (AIID).
  • Australasian Leukaemia and Lymphoma GroupcoreStrategic or Co-development PartnerALLG is a not-for-profit blood cancer clinical trial research group that partnered with Prof David Curtis on blood stem cell transplant research that changed 40 years of standard practice.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Alfred Research Alliance competitors and assessment

Company assessment

Direct peers

  • Brisbane Diamantina Health Partners: NHMRC-accredited AHSC covering Brisbane's major hospitals and universities (UQ, QUT). Competes with ARA for translational research scale and industry-sponsored trials in Australia.
  • Parkville Precinct Partnership (WEHI, Peter Mac, Doherty Institute, Melbourne Neuroscience Centre): Major Melbourne biomedical research cluster around Walter and Eliza Hall Institute, Peter MacCallum Cancer Centre, and the Doherty Institute. Comparable in scale to ARA, focused on cancer, immunology, and infectious disease, offering an alternative precinct for researchers and industry CRO partnerships.
  • King's Health Partners (London): UK-based academic health science centre combining King's College London, Guy's and St Thomas', King's College Hospital, and South London and Maudsley. Closest international analog to ARA's AMC-affiliated consortium structure with translational research focus.
  • Monash Partners Academic Health Science Centre: NHMRC-accredited AHSC spanning Monash Health, Monash University, Hudson Institute, and other partners. Overlaps significantly with ARA given Monash University's dual membership; competes for translational research funding and clinical trial activity in Melbourne.
  • Melbourne Academic Centre for Health (MACH): MACH is a Victorian NHMRC-accredited Advanced Health Research and Translation Centre linking several Melbourne hospitals and universities — the same AMC-affiliated consortium model as ARA. Directly comparable as a competing Melbourne-based academic health science partnership focused on translational research.
  • Sydney Health Partners: NHMRC-accredited AHSC bringing together several Sydney-based hospitals, universities, and research institutes. Closest geographic peer for translational research funding and clinical trial competition in Australia's largest metro market.

Emerging players

  • Francis Crick Institute: London-based biomedical discovery research institute with strong translational focus and major funder partnerships (Wellcome, CRUK, MRC). Comparable in biomedical research density and public-private funding model, though structured as a single institute rather than a consortium.

Regional players

  • South Australian Health and Medical Research Institute (SAHMRI): Major state-based biomedical research institute in Adelaide that similarly aggregates research infrastructure, clinical trial activity, and university partnerships. Operates in a different metro market but is structurally analogous as a multi-stakeholder research enterprise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Alfred Research Alliance social profiles

Digital presence

Alfred Research Alliance compliance and trust

Trust signal

Compliance7 records

Alfred Research Alliance financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alfred Research Alliance leadership team

Management profile

Number of profiles

Profiles1 record

Alfred Research Alliance funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alfred Research Alliance M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alfred Research Alliance

What does Alfred Research Alliance do?

Alfred Research Alliance is a consortium of eight healthcare, university, and medical research organizations operating a co-located biomedical research precinct in Melbourne. It delivers translational research, clinical trials (including first-in-human studies), specialized research platform services (flow cytometry, preclinical imaging, biobanks, bioinformatics), and postgraduate education programs. Activities span basic science, clinical trials, and public health implementation, supported by $332M in annual external research funding.

Is Alfred Research Alliance a public or private company?

Alfred Research Alliance is a private company. It is classified as unknown and is currently operating.

When was Alfred Research Alliance founded?

Alfred Research Alliance was founded in 1995. It employs 1 to 10 people.

Where is Alfred Research Alliance based?

Alfred Research Alliance is headquartered in Melbourne, Australia, in the Oceania region.

How does Alfred Research Alliance make money?

Four revenue lines are on record. Research Grants and Funding is the primary driver. The others are clinical Trial Services, education and Training and platform Services and Facilities Access.

Who are Alfred Research Alliance's main competitors?

Direct peers on record are Brisbane Diamantina Health Partners, Parkville Precinct Partnership (WEHI, Peter Mac, Doherty Institute, Melbourne Neuroscience Centre), King's Health Partners (London), Monash Partners Academic Health Science Centre, Melbourne Academic Centre for Health (MACH) and Sydney Health Partners. Francis Crick Institute is listed as an emerging player. South Australian Health and Medical Research Institute (SAHMRI) is listed as a regional player.

Does Alfred Research Alliance have an API?

No public API is recorded for Alfred Research Alliance.

What industry is Alfred Research Alliance in?

Alfred Research Alliance's product category is Biomedical Research Services. Its primary akta.pro industry code is EDAHAGAI, Biomedical Sciences & Medical Research Institutes (University-Based), with a secondary code of HLAGACAE, Clinical Trial Site Operations & Study Coordination. Its NAICS code is 5417 and its SIC code is 8600.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales